Who are Elocon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natazia, Faslodex, Ortho Evra, Gynorest, Progesterone, Aygestin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mometasone-furoate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Elocon — Competitive Intelligence Brief

Elocon (MOMETASONE FUROATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid. Area: Oncology.

marketed Corticosteroid Progesterone receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Elocon (MOMETASONE FUROATE) — Merck & Co.. Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Elocon TARGET	MOMETASONE FUROATE	Merck & Co.	marketed	Corticosteroid	Progesterone receptor	1987-01-01
Natazia	DIENOGEST	Mochida Pharmaceutical Co., Ltd.	marketed	Progestin	Progesterone receptor	2010-01-01
Faslodex	fulvestrant	AstraZeneca	marketed	Estrogen Receptor Antagonist [EPC]	Progesterone receptor	2002-01-01
Ortho Evra	NORELGESTROMIN		marketed	Estrogen [EPC]	Progesterone receptor	2001-01-01
Gynorest	DYDROGESTERONE	Solvay	marketed	dydrogesterone	Progesterone receptor	1982-01-01
Progesterone	Progesterone plus HCG	Dunamenti REK Istenhegyi IVF Center	marketed	Progesterone [EPC]	progesterone receptor, luteinizing hormone/choriogonadotropin receptor	1978-01-01
Aygestin	NORETHINDRONE ACETATE	Duramed Res	marketed	Estrogen [EPC]	Progesterone receptor	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-29 — Elocon · 7544192 · Method of Use · US
2027-06-12 — Elocon · 8025635 · Formulation · US
2028-01-30 — Natazia · 8153616 · US
2031-10-03 — Elocon · 10357640 · Method of Use · US
2032-02-08 — Elocon · 8763222 · Formulation · US
2034-02-14 — Faslodex · 10188663 · Formulation · US
2034-02-14 — Faslodex · 9833459 · Formulation · US
2034-03-13 — Elocon · 10406332 · Formulation · US
2034-05-17 — Faslodex · 9271990 · Formulation · US
2034-11-24 — Elocon · 10232152 · Formulation · US

Sponsor landscape (Corticosteroid class)

· 22 drugs in this class
Pfizer · 9 drugs in this class
Chiesi Farmaceutici S.p.A. · 6 drugs in this class
Assistance Publique - Hôpitaux de Paris · 6 drugs in this class
Merck & Co. · 5 drugs in this class
LEO Pharma · 4 drugs in this class
Allergan · 4 drugs in this class
AbbVie · 4 drugs in this class
Bristol-Myers Squibb · 3 drugs in this class
Bausch Health · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elocon — Competitive Intelligence Brief. https://druglandscape.com/ci/mometasone-furoate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab